PMID- 17633393
OWN - NLM
STAT- MEDLINE
DCOM- 20071206
LR  - 20151119
IS  - 1427-440X (Print)
IS  - 1427-440X (Linking)
VI  - 52
IP  - 2
DP  - 2006
TI  - [Her-2 amplification and p185 expression in invasive breast cancer cells in 
      women].
PG  - 5-12
AB  - INTRODUCTION: The objective of the investigation was to describe p185 protein 
      expression using immunohistochemistry (IHC) and HER-2 gene amplification by 
      fluorescence in situ hybridization (FISH), assessment being semi-quantitative and 
      with the more precise computer image analysis, and to determine whether p185 
      overexpression is associated with some clinical and morphological parameters such 
      as histological type, histological grade, axillary lymph node status, tumor size, 
      estrogen receptor expression, proliferative index, and age in females with 
      invasive breast carcinoma. MATERIAL AND METHODS: Histological preparations from 
      390 breast carcinomas were studied with the IHC reaction (HercepTest) based on a 
      polyclonal anti-p185 antibody. HercepTest results classified semi-quantitatively 
      as 2+ and 3+ were evaluated using a computer image analyzer and the p185 index 
      was calculated. HER-2 amplification was carried out with FISH using a unique 
      probe (HER-2) with a satellite probe (CEP17). The FISH reaction was assessed 
      routinely by counting red fluorescence signals emitted by the HER-2 gene and 
      additionally with AnalySIS software (AS). The latter method showed that the mean 
      HER-2 amplification index in carcinomas determined as 2+ was significantly lower 
      as compared to carcinomas defined as 3+ (p < 0.0001). On the other hand, the mean 
      amplification indices of carcinomas classified as 3+ and of 2+ cancers which 
      manifested HER-2 amplification did not differ significantly. High HER-2 
      amplification values (HER-2/CEP17 > 5) were noted in a similar percentage of 
      carcinomas classified by IHC as 2+ (45.5%) or 3+ (55.5%). No correlation was 
      observed between the intensity of the immunohistochemical reaction to p185 as 
      assessed by computer image analysis and the HER-2 amplification index either in 
      breast carcinomas classified semi-quantitatively as 2+ or 3+. The p185 index in 
      2+ carcinomas without HER-2 amplification might be higher than in some cancers 
      with HER-2 amplification or even higher than in some carcinomas with HER-2 
      amplification belonging to the 3+ class. Significant differences were noted in 
      p185 expression between ductal and lobular carcinomas (p = 0.0001) and between 
      lobular and medullar carcinomas (p = 0.003). Invasive ductal carcinomas revealed 
      significant differences in p185 expression depending on histological grade (I 
      degree vs III degree p = 0.02; II degree vs III degree p = 0.02), estrogen 
      receptor expression (p = 0.01), and proliferative index (p = 0.02).
FAU - Titi, Sami
AU  - Titi S
AD  - Zaklad Patomorfologii Pomorskiej Akademii Medycznej, Szczecin.
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Amplifikacja HER-2 I ekspresja p185 w komorkach inwazyjnych rakow sutka u kobiet.
PL  - Poland
TA  - Ann Acad Med Stetin
JT  - Annales Academiae Medicae Stetinensis
JID - 7506854
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Biomarkers, Tumor
MH  - Breast Neoplasms/*genetics/pathology
MH  - Carcinoma, Ductal, Breast/*genetics/pathology
MH  - Carcinoma, Intraductal, Noninfiltrating/genetics/pathology
MH  - Carcinoma, Lobular/*genetics/pathology
MH  - Female
MH  - *Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Image Processing, Computer-Assisted/instrumentation
MH  - Immunohistochemistry/instrumentation/standards
MH  - In Situ Hybridization, Fluorescence/instrumentation
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptors, Estrogen
EDAT- 2007/07/18 09:00
MHDA- 2007/12/07 09:00
CRDT- 2007/07/18 09:00
PHST- 2007/07/18 09:00 [pubmed]
PHST- 2007/12/07 09:00 [medline]
PHST- 2007/07/18 09:00 [entrez]
PST - ppublish
SO  - Ann Acad Med Stetin. 2006;52(2):5-12.